

Economic cost of delayed access to 14 new cancer medicines in Canada's public drug plans.

Description

Author: Nigel SB Rawson, Ph.D.

The aim of this analysis is to estimate the number of potential patients impacted by provincial drug insurance coverage delays for a number of selected oncology drugs approved between 2010 and 2013 and the associated economic cost of these delays.

Revisions: This paper was revised to reflect additional information as of August 24, 2016.